Genmab A/S (NASDAQ:GMAB) Given Equal Weight Rating at Morgan Stanley

Morgan Stanley reaffirmed their equal weight rating on shares of Genmab A/S (NASDAQ:GMAB) in a report published on Monday,Benzinga reports. Morgan Stanley currently has a $34.00 target price on the stock.

Several other research analysts have also commented on GMAB. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. HC Wainwright reissued a “buy” rating and set a $39.00 price objective on shares of Genmab A/S in a research report on Wednesday, January 28th. Finally, Truist Financial restated a “buy” rating and issued a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Genmab A/S has an average rating of “Hold” and a consensus price target of $41.00.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $30.03 on Monday. The stock’s 50-day moving average is $32.31 and its two-hundred day moving average is $29.82. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $35.43. The firm has a market cap of $19.29 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 17.63 and a beta of 0.90.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Founders Capital Management raised its holdings in Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Parallel Advisors LLC increased its position in Genmab A/S by 11.3% during the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the period. CWM LLC raised its stake in shares of Genmab A/S by 18.8% during the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after buying an additional 433 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after buying an additional 440 shares during the period. Finally, Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.